Ambulatory blood pressure parameters after canrenone addition to existing treatment regimens with maximum tolerated dose of angiotensin-converting enzyme inhibitors/angiotensin II type 1 receptor blockers plus hydrochlorothiazide in uncontrolled hypertensive patients

References

• FreisEDHypertension and atherosclerosisAm J Med1969465 735 7404892339
   PubMed Web of Science ®Google Scholar
• CongiuTSchembriLTozziMScanning electron microscopy examination of endothelium morphology in human carotid plaquesMicron2010415 532 53620207549
   PubMed Web of Science ®Google Scholar
• PiepoliMFHoesAWAgewallS2016European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)Eur Heart J Epub2016523
   Google Scholar
• KotsevaKWoodDDe BacquerDEUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countriesEur J Prev Cardiol2016236 636 64825687109
   PubMed Web of Science ®Google Scholar
• FalconeCBozziniSGuastiLSoluble RAGE plasma levels in patients with coronary artery disease and peripheral artery diseaseSci World J20132013 584504
   Web of Science ®Google Scholar
• GuastiLMarescaAMSchembriLRelationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatmentBMC Cardiovasc Disord201616 2626822994
   PubMed Web of Science ®Google Scholar
• GuastiLMarinoFCosentinoMCytokine production from peripheral blood mononuclear cells and polymorphonuclear leukocytes in patients studied for suspected obstructive sleep apneaSleep Breath2011151 3 1119924457
   PubMed Web of Science ®Google Scholar
• MarinoFGuastiLCosentinoMThyroid hormone and thyrotropin regulate intracellular free calcium concentrations in human polymorphonuclear leukocytes: in vivo and in vitro studiesInt J Immunopathol Pharmacol2006191 149 16016569353
   PubMed Web of Science ®Google Scholar
• Patarroyo AponteMMFrancisGSEffect of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in atherosclerosis preventionCurr Cardiol Rep2012144 433 44222562592
   PubMed Web of Science ®Google Scholar
• MarinoFGuastiLCosentinoMAngiotensin II type 1 receptor expression in polymorphonuclear leukocytes from high-risk subjects: changes after treatment with simvastatinJ Cardiovasc Pharmacol2007495 299 30517513949
   PubMed Web of Science ®Google Scholar
• MarinoFMarescaAMCosentinoMAngiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatmentCardiovasc Diabetol201211 15323259529
   PubMed Web of Science ®Google Scholar
• MarinoFGuastiLTozziMAngiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial diseaseJ Cardiovasc Pharmacol2009546 520 52519755917
   PubMed Web of Science ®Google Scholar
• FerrarioCMSchiffrinELRole of mineralocorticoid receptor antagonists in cardiovascular diseaseCirc Res20151161 206 21325552697
   PubMed Web of Science ®Google Scholar
• NgKPArnoldJSharifACardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: a systematic review and meta-analysis of randomized trialsJ Renin Angiotensin Aldosterone Syst2015163 599 61325784710
   PubMed Web of Science ®Google Scholar
• BrietMSchiffrinELVascular actions of aldosteroneJ Vasc Res2013502 89 9923172373
   PubMed Web of Science ®Google Scholar
• McGrawAPMcCurleyAPrestonIRJaffeIZMineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implicationsCurr Atheroscler Rep2013157 34023719923
   PubMed Web of Science ®Google Scholar
• Te RietLvan EschJHRoksAJvan den MeirackerAHDanserAHHypertension: renin-angiotensin-aldosterone system alterationsCirc Res20151166 960 97525767283
   PubMed Web of Science ®Google Scholar
• GrandiAMSolbiatiFLauritaEEffects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot studyAm J Hypertens2008212 231 23718174880
   PubMed Web of Science ®Google Scholar
• SartoriMCalòLAMascagnaVAldosterone and refractory hypertension: a prospective cohort studyAm J Hypertens2006194 373 37916580572
   PubMed Web of Science ®Google Scholar
• VasanRSEvansJCLarsonMGSerum aldosterone and the incidence of hypertension in nonhypertensive personsN Engl J Med20043511 33 4115229305
   PubMed Web of Science ®Google Scholar
• VongpatanasinWResistant hypertension: a review of diagnosis and managementJAMA201431121 2216 222424893089
   PubMed Web of Science ®Google Scholar
• LiuGZhengXXXuYLLuJHuiRTHuangXHEffect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysisJ Hum Hypertens2015293 159 16625078487
   PubMed Web of Science ®Google Scholar
• EsterasRPerez-GomezMVRodriguez-OsorioLOrtizAFernandez-FernandezBCombination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal functionTher Adv Drug Saf201564 166 17626301070
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPD’AvinoMEfficacy and safety of two dosages of Canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: the ESCAPE-IT trialCardiovasc Ther2017351 47 5427860389
   PubMed Web of Science ®Google Scholar
• ESH/ESC Task Force for the Management of Arterial Hypertension2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial HypertensionJ Hypertens20133110 1925 193824107724
   PubMed Web of Science ®Google Scholar
• KlahrSLeveyASBeckGJFor the Modification of Diet in Renal Disease Study Group: the effects of dietary protein restriction and bloodpressure control on the progression of chronic renal diseaseN Engl J Med1994330 877 8848114857
   PubMed Web of Science ®Google Scholar
• MatthewsDRHoskerJPRudenskiASNaylorBATreacherDFTurnerRCHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in manDiabetologia1985287 412 4193899825
   PubMed Web of Science ®Google Scholar
• O’BrienEWhy is it that we continue to deny patients ambulatory blood pressure monitoring?Hypertension2016673 484 48726729751
   PubMed Web of Science ®Google Scholar
• SiuALU.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statementAnn Intern Med201516310 778 78626458123
   PubMed Web of Science ®Google Scholar
• BakrisGLLindholmLHBlackHRDivergent results using clinic and ambulatory blood pressures: report of adarusentan-resistant hypertension trialHypertension2010565 824 83020921430
   PubMed Web of Science ®Google Scholar
• NiXZhangJZhangPEffects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled studyJ Clin Hypertens (Greenwich)2014169 658 66325052724
   PubMed Web of Science ®Google Scholar
• WhiteWBCarrAAKrauseSJordanRRonikerBOigmanWAssessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertensionAm J Cardiol2003921 38 4212842242
   PubMed Web of Science ®Google Scholar
• VáclavíkJSedlákRPlachyMAddition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trialHypertension2011576 1069 107521536989
   PubMed Web of Science ®Google Scholar
• FlackJMOparilSPrattJHEfficacy and tolerability of eplerenone and losartan in hypertensive black and white patientsJ Am Coll Cardiol2003417 1148 115512679215
   PubMed Web of Science ®Google Scholar
• de SouzaFMuxfeldtEFiszmanRSallesGEfficacy of spironolactone therapy in patients with true resistant hypertensionHypertension2010551 147 15219858405
   PubMed Web of Science ®Google Scholar
• SuzukiHShutoHShutoCEplerenone, an aldosterone blocker, is more effective in reducing blood pressure in patients with, than without, metabolic syndromeTher Adv Cardiovasc Dis201264 141 14722751654
   PubMedGoogle Scholar
• BombackASMuskalaPBaldEChwatkoGNowickiMLow-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damageClin Nephrol2009726 449 45619954722
   PubMed Web of Science ®Google Scholar
• PellicciaFRosanoGPattiGVolterraniMGrecoCGaudioCEfficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertensionInt J Cardiol2015200 8 1125466561
   PubMed Web of Science ®Google Scholar
• PellicciaFPattiGRosanoGGrecoCGaudioCEfficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysisInt J Cardiol20141771 219 22825499383
   PubMed Web of Science ®Google Scholar
• RosaJWidimskýPToušekPRandomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 studyHypertension2015652 407 41325421981
   PubMed Web of Science ®Google Scholar
• O’BrienEParatiGStergiouGEuropean Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoringJ Hypertens2013319 1731 176824029863
   PubMed Web of Science ®Google Scholar
• SafarMEPlanteGEMimranAArterial stiffness, pulse pressure, and the kidneyAm J Hypertens2015285 561 56925480804
   PubMed Web of Science ®Google Scholar
• WangYHuYLiYAssociation of renal function with the ambulatory arterial stiffness index and pulse pressure in hypertensive patientsHypertens Res2012352 201 20622011684
   PubMed Web of Science ®Google Scholar
• SelvarajSStegPGElbezYPulse pressure and risk for cardiovascular events in patients with atherothrombosis: from the REACH RegistryJ Am Coll Cardiol2016674 392 40326821627
   PubMed Web of Science ®Google Scholar
• GrandiAMImperialeDSantilloRAldosterone antagonist improves diastolic function in essential hypertensionHypertension2002405 647 65212411457
   PubMed Web of Science ®Google Scholar
• de SimoneGChinaliMMuredduGFEffect of canrenone on left ventricular mechanics in patients with mild systolic heart failure and metabolic syndrome: the AREA-in-CHF studyNutr Metab Cardiovasc Dis20112110 783 79121939839
   PubMed Web of Science ®Google Scholar
• PandeyAGargSMatuleviciusSAEffect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic reviewJ Am Heart Assoc2015410 e00213726459931
   PubMed Web of Science ®Google Scholar
• KohKKHanSHOhPCShinEKQuonMJCombination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interactionAtherosclerosis20102092 307 31319800624
   PubMed Web of Science ®Google Scholar
• ChaugaiSSherpaLYSepehryAAArimaHWangDWEffect of RAAS blockers on adverse clinical outcomes in high CVD risk subjects with atrial fibrillation: a meta-analysis and systematic review of randomized controlled trialsMedicine (Baltimore)20169526 e405927368043
   PubMed Web of Science ®Google Scholar
• DentaliFGianniMSquizzatoAUse of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta analysisThromb Haemost2011106 363 37021614408
   PubMed Web of Science ®Google Scholar